



Stereoselective synthesis of (1*S*,3*R*,4*R*)-4-acetoxy-3-(2'-fluoro-1'-trimethylsilyloxyethyl)-2-azetidinone

Ivan Plantan^a, Michel Stephan^b, Uroš Urleb^a, Barbara Mohar^{b,*}

^a Lek Pharmaceuticals d.d., Verovškova 57, SI-1526 Ljubljana, Slovenia

^b Laboratory of Organic and Medicinal Chemistry, National Institute of Chemistry, Hajdrihova 19, SI-1001 Ljubljana, Slovenia

ARTICLE INFO

Article history:

Received 10 December 2008

Revised 11 March 2009

Accepted 17 March 2009

Available online 21 March 2009


ABSTRACT

A stereoselective synthesis of (1*S*,3*R*,4*R*)-4-acetoxy-3-(2'-fluoro-1'-trimethylsilyloxyethyl)-2-azetidinone as a new fluorine-containing intermediate towards β -lactams, is described. The synthetic key step relies upon the dynamic kinetic resolution (DKR) of ethyl 2-benzamidomethyl-4-fluoro-3-oxo-butanoate via asymmetric transfer hydrogenation catalyzed by [Ru(η^6 -arene)(*S,S*)-R₂NSO₂DPEN].

© 2009 Elsevier Ltd. All rights reserved.

The 2-azetidinone moiety is present in a large number of important biologically active compounds of which β -lactam antibiotics are representative. Despite the rapid increase in the resistance of microorganisms to current antibiotics, β -lactam antibiotics still represent more than half of available antibacterial agents.¹ Moreover, owing to the unique properties attributed to the fluorine atom, selectively fluorinated organic intermediates constitute challenging targets which are useful towards the synthesis of biologically active substances with modified properties.²

The use of asymmetric catalysis has led to several industrial processes on a multi-ton scale. One of the earliest and most referred to being the process for the synthesis of the precursor to carbapenems by the Takasago Co. Relying upon the Ru-(BINAP)-catalyzed asymmetric hydrogenation of a β -keto ester derivative via dynamic kinetic resolution (DKR), the optically pure (3*R*,4*R*)-4-acetoxy-3-[(*R*)-(tert-butylidimethylsilyloxy)ethyl]-2-azetidinone (**1**) precursor was prepared.³ In the subsequent step, the acetoxy group was displaced readily by nucleophiles with high stereocontrol aided by the presence of the bulky *O*-TBDMS protecting group.⁴




In our ongoing research on trinems (i.e., tricyclic β -lactams) with improved biological properties,⁵ we devised a synthetic strategy towards the preparation of highly optically active fluorine-containing

reactive 4-acetoxy-azetidinones.⁶ A literature survey revealed only a few cases of the preparation of such intermediates.⁷

Herein, we present our synthesis of the new fluoroalkyl acetoxy azetidinone **2** (Scheme 1) via a modified procedure to that developed by the Takasago Co. for the synthesis of **1**.

Thus, ethyl 2-benzamidomethyl-4-fluoro-3-oxo-butanoate (**4**), prepared by alkylation of commercially available ethyl γ -fluoro-acetoacetate (**3**),⁸ was subjected to asymmetric transfer hydrogenation⁹ using the Mohar–Stephan [Ru(η^6 -arene)(*S,S*)-R₂NSO₂DPEN] catalyst (R₂NSO₂DPEN = *N*-sulfamoyl-1,2-diphenylethylenediamine). Asymmetric hydrogenation of **4** using Ru-BINAP as catalyst gave poorer results than using the latter asymmetric transfer hydrogenation.¹⁰



Scheme 1. Reagents and conditions: (a) LiH, BzNHCH₂Cl, THF, 0 °C → rt; (b) [Ru(1,3,5-Et₃C₆H₃)(*S,S*)-Me₂NSO₂DPEN], HCO₂H-Et₃N (5:2), DMF, rt; (c) (i) 10% aq HCl, reflux; (ii) Et₃N, MeOH, rt; (d) (2-PyS)₂, PPh₃, DMSO, 90 °C; (e) RuCl₃·xH₂O, NaOAc, AcOOH, PrOAc, -40 °C → -10 °C; (f) (i) TMSCN, DMF, rt; (ii) Buffered silica gel (pH 8), CH₂Cl₂, rt, (>99% dr, 96% ee); (g) DEAD, PPh₃, CH₂Cl₂, rt; (h) (*R*)- or (*S*)-PhCH(OMe)CO₂H, DCC, DMAP, CH₂Cl₂, rt.

* Corresponding author. Tel.: +386 147 60 250; fax: +386 147 60 300.
E-mail address: barbara.mohar@ki.si (B. Mohar).

Table 1
[Ru(η^6 -arene)(S,S)-R₂NSO₂DPEN]-catalyzed transfer hydrogenation of **4**^a

Entry	[RuCl ₂ (η^6 -arene)] ₂ arene=	Ligand	syn/anti ^b	ee (syn, %) ^c
1	1,3,5-Triethylbenzene	a	83:17	96
2	Hexamethylbenzene	a	71:29	96
3	Benzene	b	76:24	74
4	Mesitylene	b	71:29	93
5	1,3,5-Triethylbenzene	b	75:25	95
6	Hexamethylbenzene	b	83:17	95
7	Hexamethylbenzene	c	74:26	94

^a HCO₂H–Et₃N (5:2, 250 μ L) was added to a mixture of **4** (1 mmol) and performed [RuCl(η^6 -arene)(S,S)-R₂NSO₂DPEN] (0.5 mol %) in DMF (1 mL), and the reaction was stirred at rt for 1 d to attain 100% conversion.

^b Determined by ¹⁹F NMR spectroscopy: δ (syn) = –231, δ (anti) = –228.

^c Determined by HPLC analysis on a chiralcel OD column with hexane/2-PrOH/CF₃CO₂H 97:3:0.2 (1 mL/min) and UV (λ = 222 nm) detection: *t*(R,R) = 44 min, *t*(S,S) = 58 min.

Asymmetric transfer hydrogenation of **4** in the presence of HCO₂H–Et₃N (5:2) was performed at rt using 0.5% of the in situ generated catalyst which was prepared from [RuCl₂(η^6 -arene)]₂ and (S,S)-R₂NSO₂DPEN ligand in DMF at 80 °C. Screening various catalysts (Table 1) led to the optimum result using [RuCl₂(1,3,5-Et₃C₆H₃)₂] and (S,S)-Me₂NSO₂DPEN. The efficiency of this transformation resides in the highly stereoselective DKR leading to the formation of **5** in 83:17 dr (syn/anti) and in quantitative yield. Pure syn-**5** was easily isolated in 60% yield after a single column chromatography eluting with CH₂Cl₂/Et₂O (4:1) and chiral HPLC analysis revealed an ee of 96%.

The syn-(2S,3S) configuration of the major diastereomer **5** was confirmed by a combination of ¹H NMR NOE analysis of its dehydrated derivative **9** (prepared under Mitsunobu conditions¹¹–Scheme 1, step g) which showed *E*-geometry, and in the subsequent synthetic steps, by ¹H NMR analysis using an improved Mosher method¹² involving the *O*-methyl-(*R*)- and *O*-methyl-(*S*)-mandelates of **7**.

In the following step, syn-**5** was subjected to hydrolysis in boiling 10% aq HCl to give the corresponding hydrochloride salt of β -amino acid **6**. After treatment of the residue with Et₃N in MeOH, β -amino acid **6** was isolated in 65% yield. Azetidinone formation employing 2,2'-dipyridyl disulfide and PPh₃ in DMSO at 90 °C and crucial slow addition of **6** in DMSO, resulted in the formation of **7** in 60% isolated yield. We utilized the modified Ohno conditions¹³ as we previously noted a partial loss of fluorine while monitoring the reaction progress by ¹⁹F NMR (α,α,α -trifluorotoluene was used as the internal standard). HPLC analysis of the **7**-*O*-Me-(*R*)-mandelate revealed a diastereomeric ratio of 98:2, and 96% ee for **7**. This result indicates the retention of the stereochemistry during the transformation sequence of syn-**5** having 96% ee.

Protection of **7** using TBDMSCl/Et₃N led to the preferential formation of the *N*-TBDMS-protected compound. Due to this unexpected result, the preparation of **2** was carried out by direct peracetic acid oxidation of **7** catalyzed by RuCl₃·xH₂O followed by *O*-TMS-protection. Under these conditions, the acetoxylation proceeded smoothly furnishing **8** in a 4:1 trans/cis ratio as confirmed by ¹H and ¹⁹F NMR. This mixture was subjected to treat-

ment with trimethylsilyl cyanide in DMF under mild conditions affording the crude *N,O*-bis-TMS-protected derivative of **8**, which yielded in turn the desired *O*-TMS-protected compound **2** via selective *N*-desilylation using buffered silica gel (pH 8).¹⁴ Column chromatography on buffered silica gel (pH 8) with gradient elution (hexane/CH₂Cl₂) allowed the isolation of **2** as a single diastereomer in 57% yield and with high chemical purity.

In summary, (1'*S*,3*R*,4*R*)-4-acetoxy-3-(2'-fluoro-1'-trimethylsilyloxyethyl)-2-azetidinone (**2**) was prepared in 96% ee relying upon asymmetric transfer hydrogenation as the key step using HCO₂H–Et₃N (5:2) and catalyzed with 0.5% [Ru(1,3,5-Et₃C₆H₃)(S,S)-Me₂NSO₂DPEN]. The application of this reactive intermediate in the synthesis of fluorine-containing trinems is under study and the results will be communicated shortly.

Supplementary data

Supplementary data (experimental procedures and characterization data for all new compounds) associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2009.03.111.

References and notes

- (a) Bonfiglio, G.; Russo, G.; Nicoletti, G. *Expert Opin. Invest. Drugs* **2002**, *11*, 529–544; (b) Deshmukh, A. R. A. S.; Bhawal, B. M.; Krishnaswamy, D.; Govande, V. V.; Shinkre, B. A.; Jayanthi, A. *Curr. Med. Chem.* **2004**, *11*, 1889–1920; (c) Yoneyama, H.; Katsumata, R. *Biosci. Biotechnol. Biochem.* **2006**, *70*, 1060–1075.
- (a) *Enantiocontrolled Synthesis of Fluoro-organic Compounds*; Soloshonok, V. A., Ed.; Wiley: Chichester, 1999; (b) Mikami, K. In *Asymmetric Fluoroorganic Chemistry: Synthesis, Application and Future Directions*; Ramachandran, P. V., Ed.; American Chemical Society: Washington, DC, 2000; pp 255–269; (c) Mikami, K.; Itoh, Y.; Yamanaka, M. *Chem. Rev.* **2004**, *104*, 1–16.
- Mashima, K.; Matsumura, Y.; Kusano, K.; Kumobayashi, H.; Sayo, N.; Hori, Y.; Ishizaki, T.; Akutagawa, S.; Takaya, H. *J. Chem. Soc., Chem. Commun.* **1991**, 609–610. Therein, the best catalyst: Ru-(3,5-*t*Bu₂-binap) led to 99:1 dr and 99% ee.
- See the following articles and references cited therein: (a) Berks, A. H. *Tetrahedron* **1996**, *52*, 331–375; (b) Rossi, T.; Marchioro, C.; Paio, A.; Thomas, R. J.; Zaranonello, P. *J. Org. Chem.* **1997**, *62*, 1653–1661.
- (a) Čopar, A.; Prevec, T.; Anžič, B.; Mesar, T.; Selič, L.; Vilar, M.; Šolmajer, T. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 971–975; (b) Plantan, I.; Selič, L.; Mesar, T.; Štefanič, A. P.; Oblak, M.; Preželj, A.; Hesse, L.; Andrejašič, M.; Vilar, M.; Turk, D.; Kocijan, A.; Prevec, T.; Vilfan, G.; Kocijan, D.; Čopar, A.; Urleb, U.; Šolmajer, T. *J. Med. Chem.* **2007**, *50*, 4113–4121.
- Plantan, I.; Preželj, A.; Urleb, U.; Mohar, B.; Stephan, M. *Eur. Pat. Appl. EP 158454*, 2008.
- (a) Welch, J. T.; Araki, K.; Kaweck, R.; Wichtowski, J. A. *J. Org. Chem.* **1993**, *58*, 2454–2462; (b) Abouabdellah, A.; Welch, J. T. *Tetrahedron: Asymmetry* **1994**, *5*, 1005–1013; (c) Antolini, L.; Forni, A.; Davoli, P.; Moretti, I.; Prati, F. *Tetrahedron: Asymmetry* **1998**, *9*, 285–292.
- (a) Bergmann, E. D.; Cohen, S.; Shahak, I. *J. Chem. Soc.* **1959**, 3278–3285; (b) Available from Narchem, USA.
- (a) Šterk, D.; Stephan, M. S.; Mohar, B. *Tetrahedron: Asymmetry* **2002**, *13*, 2605–2608; (b) *Catalysts for Fine Chemical Synthesis*; Roberts, S. M., Whittall, J., Eds.; John Wiley & Sons, 2007; Vol. 5, pp 113–116.
- In our hands, hydrogenation of **4** in MeOH under 50 atm of H₂ at rt using 1% of [RuCl(binap)(dmf)₃]Cl and [Ru]₂(binap)] yielded, after complete conversion, syn/anti ratios of 90:10 (80% ee for syn) and 94:6 (50% ee for syn), respectively.
- Mitsunobu, O. *Synthesis* **1981**, 1–28.
- ¹H NMR analysis applying the modified Mosher method using *O*-methyl-(*R*)- and *O*-methyl-(*S*)-mandelates of **7**, gave $\Delta\delta^{RS}$ = –0.31 and –0.36 ppm for H_a-4 and H_b-4, respectively, and $\Delta\delta^{RS}$ = 0.08 and 0.14 ppm for H_{a,b}-2', revealing a (1'*S*,4*S*) configuration for azetidinone **7**. This corresponds to the (2*S*,3*S*) configuration for syn-**5**. For a detailed explanation of this method, see: (a) Latypov, S.; Seco, J. M.; Quiñoá, E.; Riguera, R. *J. Org. Chem.* **1995**, *60*, 504–515; (b) Seco, J. M.; Quiñoá, E.; Riguera, R. *Chem. Rev.* **2004**, *104*, 17–118.
- Kobayashi, S.; Iimori, T.; Izawa, T.; Ohno, M. *J. Am. Chem. Soc.* **1981**, *103*, 2406–2408.
- Armarego, W. L. F.; Chai, C. L. L. *Purification of Laboratory Chemicals*; Elsevier, 2003, p. 20.